DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 189 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $475,310 | -11.7% | 29,000 | 0.0% | 0.01% | 0.0% |
Q3 2022 | $538,000 | +41.2% | 29,000 | 0.0% | 0.01% | +40.0% |
Q2 2022 | $381,000 | -81.9% | 29,000 | -86.5% | 0.01% | -78.3% |
Q4 2021 | $2,101,000 | -18.2% | 215,000 | +184.4% | 0.02% | -20.7% |
Q3 2021 | $2,569,000 | -14.9% | 75,603 | -8.4% | 0.03% | -27.5% |
Q2 2021 | $3,020,000 | +10.1% | 82,500 | +35.0% | 0.04% | -32.2% |
Q1 2021 | $2,742,000 | -31.4% | 61,100 | -12.7% | 0.06% | -35.9% |
Q4 2020 | $3,996,000 | -13.5% | 70,000 | -22.2% | 0.09% | -14.8% |
Q3 2020 | $4,619,000 | -40.5% | 90,000 | -30.8% | 0.11% | -58.1% |
Q2 2020 | $7,766,000 | +45.2% | 130,000 | 0.0% | 0.26% | -14.6% |
Q1 2020 | $5,350,000 | -42.7% | 130,000 | -13.3% | 0.30% | -3.5% |
Q4 2019 | $9,332,000 | +587.2% | 149,900 | +274.8% | 0.31% | +347.1% |
Q3 2019 | $1,358,000 | -85.9% | 40,000 | -90.7% | 0.07% | -85.6% |
Q2 2019 | $9,649,000 | – | 427,900 | – | 0.49% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |